$CADL
Candel Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024126767 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $5.416M
YoY Change -7.34%
% of Gross Profit
Depreciation & Amortization $200.0K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $8.757M
YoY Change -1.17%
Operating Profit -$8.757M
YoY Change -1.17%
Interest Expense $487.0K
YoY Change -27.2%
% of Operating Profit
Other Income/Expense, Net -$1.889M
YoY Change -543.43%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$10.65M
YoY Change 26.21%
Net Earnings / Revenue
Basic Earnings Per Share -$0.33
Diluted Earnings Per Share -$0.33
COMMON SHARES
Basic Shares Outstanding 32.48M 32.08M
Diluted Shares Outstanding 32.01M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $16.60M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $18.09M
YoY Change -59.9%
LONG-TERM ASSETS
Property, Plant & Equipment $2.477M
YoY Change -32.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.432M
YoY Change -30.81%
TOTAL ASSETS
Total Short-Term Assets $18.09M
Total Long-Term Assets $3.432M
Total Assets $21.52M
YoY Change -57.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $296.0K
YoY Change 18.4%
Accrued Expenses $4.569M
YoY Change 33.25%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due $9.851M
YoY Change 61.49%
Total Short-Term Liabilities $15.27M
YoY Change 47.85%
LONG-TERM LIABILITIES
Long-Term Debt $4.225M
YoY Change -70.53%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $4.225M
YoY Change -70.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.27M
Total Long-Term Liabilities $4.225M
Total Liabilities $36.77M
YoY Change 36.0%
SHAREHOLDERS EQUITY
Retained Earnings -$178.1M
YoY Change 41.46%
Common Stock $163.3M
YoY Change 9.32%
Preferred Stock
YoY Change
Treasury Stock (at cost) $448.0K
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity -$15.26M
YoY Change
Total Liabilities & Shareholders Equity $21.52M
YoY Change -57.02%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$10.65M
YoY Change 26.21%
Depreciation, Depletion And Amortization $200.0K
YoY Change 0.0%
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001841387
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40629
dei Entity Registrant Name
EntityRegistrantName
CANDEL THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2214851
dei Entity Address Address Line1
EntityAddressAddressLine1
117 Kendrick St
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 450
dei Entity Address City Or Town
EntityAddressCityOrTown
Needham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02494
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
916-5445
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
CADL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32475537
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16558000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35413000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1527000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1384000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
18085000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
36797000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2477000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3206000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
614000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
816000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
266000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
266000
CY2024Q3 us-gaap Other Assets
OtherAssets
75000
CY2023Q4 us-gaap Other Assets
OtherAssets
116000
CY2024Q3 us-gaap Assets
Assets
21517000
CY2023Q4 us-gaap Assets
Assets
41201000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
296000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
422000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4569000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4356000
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
9851000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
8893000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
552000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
513000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
15268000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14184000
CY2024Q3 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
4225000
CY2023Q4 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
11632000
CY2024Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
840000
CY2023Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
751000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
555000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
973000
CY2024Q3 cadl Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
15886000
CY2023Q4 cadl Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
916000
CY2024Q3 us-gaap Liabilities
Liabilities
36774000
CY2023Q4 us-gaap Liabilities
Liabilities
28456000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32247744
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29213627
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32125136
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29091019
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
322000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
290000
CY2024Q3 us-gaap Treasury Stock Value
TreasuryStockValue
448000
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
448000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
163001000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
149931000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178132000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-137028000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-15257000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12745000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21517000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41201000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5416000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5845000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14497000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17248000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3341000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3016000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10733000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10825000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
8757000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
8861000
us-gaap Operating Expenses
OperatingExpenses
25230000
us-gaap Operating Expenses
OperatingExpenses
28073000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8757000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8861000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25230000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28073000
CY2023Q3 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
12000
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
36000
CY2024Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
236000
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
502000
us-gaap Interest And Other Income
InterestAndOtherIncome
796000
us-gaap Interest And Other Income
InterestAndOtherIncome
1666000
CY2024Q3 us-gaap Interest Expense
InterestExpense
487000
CY2023Q3 us-gaap Interest Expense
InterestExpense
669000
us-gaap Interest Expense
InterestExpense
1700000
us-gaap Interest Expense
InterestExpense
1922000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1638000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-581000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
14970000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1449000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1889000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15874000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1229000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10646000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21517000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41201000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5416000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5845000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14497000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17248000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3341000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3016000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10733000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10825000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
8757000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
8861000
us-gaap Operating Expenses
OperatingExpenses
25230000
us-gaap Operating Expenses
OperatingExpenses
28073000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8757000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8861000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28073000
CY2023Q3 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
12000
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
36000
CY2024Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
236000
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
502000
us-gaap Interest And Other Income
InterestAndOtherIncome
796000
us-gaap Interest And Other Income
InterestAndOtherIncome
1666000
CY2024Q3 us-gaap Interest Expense
InterestExpense
487000
CY2023Q3 us-gaap Interest Expense
InterestExpense
669000
us-gaap Interest Expense
InterestExpense
1700000
us-gaap Interest Expense
InterestExpense
1922000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1638000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-581000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
14970000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1449000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1889000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
426000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15874000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1229000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10646000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8435000
us-gaap Net Income Loss
NetIncomeLoss
-41104000
us-gaap Net Income Loss
NetIncomeLoss
-26844000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8435000
us-gaap Net Income Loss
NetIncomeLoss
-41104000
us-gaap Net Income Loss
NetIncomeLoss
-26844000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32013569
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32013569
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30369129
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30369129
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12745000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1319000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3212000
us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
856000
us-gaap Net Income Loss
NetIncomeLoss
-41104000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-15257000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-9972000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
103000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1074000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
110000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10646000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-15257000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
47714000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2278000
us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
-126000
us-gaap Net Income Loss
NetIncomeLoss
-26844000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
23022000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
30771000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
735000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
-49000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8435000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
23022000
us-gaap Profit Loss
ProfitLoss
-41104000
us-gaap Profit Loss
ProfitLoss
-26844000
us-gaap Depreciation
Depreciation
745000
us-gaap Depreciation
Depreciation
711000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
162000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32013569
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32013569
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30369129
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30369129
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12745000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1319000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3212000
us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
856000
us-gaap Net Income Loss
NetIncomeLoss
-41104000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-15257000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-9972000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
103000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1074000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
110000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10646000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-15257000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
47714000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2278000
us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
-126000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
23022000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
30771000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
735000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
-49000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8435000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
23022000
us-gaap Profit Loss
ProfitLoss
-41104000
us-gaap Profit Loss
ProfitLoss
-26844000
us-gaap Depreciation
Depreciation
745000
us-gaap Depreciation
Depreciation
711000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
162000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-77000
us-gaap Share Based Compensation
ShareBasedCompensation
4068000
us-gaap Share Based Compensation
ShareBasedCompensation
2152000
cadl Non Cash Lease Expense
NonCashLeaseExpense
202000
cadl Non Cash Lease Expense
NonCashLeaseExpense
177000
cadl Non Cash Interest Expense
NonCashInterestExpense
89000
cadl Non Cash Interest Expense
NonCashInterestExpense
77000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
14970000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1449000
cadl Accretion Of Debt Discount
AccretionOfDebtDiscount
218000
cadl Accretion Of Debt Discount
AccretionOfDebtDiscount
237000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-77000
us-gaap Share Based Compensation
ShareBasedCompensation
4068000
us-gaap Share Based Compensation
ShareBasedCompensation
2152000
cadl Non Cash Lease Expense
NonCashLeaseExpense
202000
cadl Non Cash Lease Expense
NonCashLeaseExpense
177000
cadl Non Cash Interest Expense
NonCashInterestExpense
89000
cadl Non Cash Interest Expense
NonCashInterestExpense
77000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
14970000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1449000
cadl Accretion Of Debt Discount
AccretionOfDebtDiscount
218000
cadl Accretion Of Debt Discount
AccretionOfDebtDiscount
237000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
143000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
230000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-41000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
139000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-129000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-127000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
213000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1247000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-36000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-379000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-343000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21209000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26822000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
410000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
157000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-253000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1319000
cadl Proceeds From Principal Payments On Term Loan
ProceedsFromPrincipalPaymentsOnTermLoan
-6667000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2367000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18855000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27075000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35679000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70324000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16824000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43249000
us-gaap Interest Paid Net
InterestPaidNet
1462000
us-gaap Interest Paid Net
InterestPaidNet
1592000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
19000
cadl Number Of Product Candidates
NumberOfProductCandidates
2
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-41000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
139000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-129000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-127000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
213000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1247000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-36000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-379000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-343000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21209000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26822000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
410000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
157000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-253000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1319000
cadl Proceeds From Principal Payments On Term Loan
ProceedsFromPrincipalPaymentsOnTermLoan
-6667000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2367000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18855000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27075000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35679000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70324000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16824000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43249000
us-gaap Interest Paid Net
InterestPaidNet
1462000
us-gaap Interest Paid Net
InterestPaidNet
1592000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
19000
cadl Number Of Product Candidates
NumberOfProductCandidates
2
us-gaap Net Income Loss
NetIncomeLoss
-41100000
us-gaap Net Income Loss
NetIncomeLoss
-26800000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178100000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16600000
us-gaap Net Income Loss
NetIncomeLoss
-41100000
us-gaap Net Income Loss
NetIncomeLoss
-26800000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178100000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16600000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Arial;min-width:fit-content;">preparation of the Company’s condensed </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Arial;min-width:fit-content;">consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include but are not limited to management’s judgments of accrued expenses, valuation of stock-based option awards, valuations of warrants, and income taxes. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
300000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Arial;min-width:fit-content;">preparation of the Company’s condensed </span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Arial;min-width:fit-content;">consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include but are not limited to management’s judgments of accrued expenses, valuation of stock-based option awards, valuations of warrants, and income taxes. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
300000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
300000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5311000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5295000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2834000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2089000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2477000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3206000
CY2024Q3 us-gaap Depreciation
Depreciation
200000
CY2023Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
700000
us-gaap Depreciation
Depreciation
700000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5311000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5295000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2834000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2089000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2477000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3206000
CY2024Q3 us-gaap Depreciation
Depreciation
200000
CY2023Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
700000
us-gaap Depreciation
Depreciation
700000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2338000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2017000
CY2024Q3 cadl Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
1501000
CY2023Q4 cadl Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
1811000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
730000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
528000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4569000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4356000
CY2022Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
5000000
CY2022Q4 cadl Cash Proceeds Amount Equal To At Least From The Issuance And Sale Of Equity Securities
CashProceedsAmountEqualToAtLeastFromTheIssuanceAndSaleOfEquitySecurities
75000000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
2500000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
10000000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
833000
CY2024Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
13333000
CY2024Q3 cadl Debt Instrument Final Payment Fee
DebtInstrumentFinalPaymentFee
900000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
989000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
90000
us-gaap Operating Lease Cost
OperatingLeaseCost
300000
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
44000
us-gaap Variable Lease Cost
VariableLeaseCost
100000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2338000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2017000
CY2024Q3 cadl Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
1501000
CY2023Q4 cadl Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
1811000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
730000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
528000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4569000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4356000
CY2022Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
5000000
CY2022Q4 cadl Cash Proceeds Amount Equal To At Least From The Issuance And Sale Of Equity Securities
CashProceedsAmountEqualToAtLeastFromTheIssuanceAndSaleOfEquitySecurities
75000000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
2500000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
10000000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
833000
CY2024Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
13333000
CY2024Q3 cadl Debt Instrument Final Payment Fee
DebtInstrumentFinalPaymentFee
900000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
989000
CY2024Q3 cadl Debt Instrument Accretion Of Debt Discount
DebtInstrumentAccretionOfDebtDiscount
832000
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
14076000
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
9851000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4225000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
90000
us-gaap Operating Lease Cost
OperatingLeaseCost
300000
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
44000
us-gaap Variable Lease Cost
VariableLeaseCost
100000
CY2024Q3 us-gaap Lease Cost
LeaseCost
100000
us-gaap Lease Cost
LeaseCost
400000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
90000
us-gaap Operating Lease Cost
OperatingLeaseCost
300000
CY2024Q3 us-gaap Lease Cost
LeaseCost
100000
us-gaap Lease Cost
LeaseCost
400000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
90000
us-gaap Operating Lease Cost
OperatingLeaseCost
300000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
35000
us-gaap Variable Lease Cost
VariableLeaseCost
100000
CY2023Q3 us-gaap Lease Cost
LeaseCost
100000
us-gaap Lease Cost
LeaseCost
400000
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
400000
us-gaap Operating Lease Payments
OperatingLeasePayments
400000
us-gaap Operating Lease Payments
OperatingLeasePayments
446000
us-gaap Operating Lease Payments
OperatingLeasePayments
434000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M24D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2024Q3 cadl Weighted Average Incremental Borrowing Rate
WeightedAverageIncrementalBorrowingRate
0.0702
CY2023Q3 cadl Weighted Average Incremental Borrowing Rate
WeightedAverageIncrementalBorrowingRate
0.0702
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
152000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
613000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
415000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1180000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
73000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1107000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
35000
us-gaap Variable Lease Cost
VariableLeaseCost
100000
CY2023Q3 us-gaap Lease Cost
LeaseCost
100000
us-gaap Lease Cost
LeaseCost
400000
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
400000
us-gaap Operating Lease Payments
OperatingLeasePayments
446000
us-gaap Operating Lease Payments
OperatingLeasePayments
434000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M24D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2023Q3 cadl Weighted Average Incremental Borrowing Rate
WeightedAverageIncrementalBorrowingRate
0.0702
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
152000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
613000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
415000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1180000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
73000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1107000
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15351074
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15952814
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15351074
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15952814
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2008379
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5666621
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.47
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M9D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
202420
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.36
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
731169
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.8
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
535917
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.36
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4601955
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M9D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
20296000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3519140
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.4
cadl Sharebased Compensation Arrangement By Sharebased Payment Award Option Unvested Weighted Average Remaining Contractual
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionUnvestedWeightedAverageRemainingContractual
P8Y4M20D
CY2024Q3 cadl Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedIntrinsicValue
4247000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
3700000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2008379
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5666621
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.47
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M9D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
202420
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.36
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
731169
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
535917
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.36
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4601955
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.55
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M9D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3519140
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.4
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M20D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
16049000
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1082815
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
3.04
cadl Sharebased Compensation Arrangement By Sharebased Payment Award Option Unvested Weighted Average Remaining Contractual
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionUnvestedWeightedAverageRemainingContractual
P8Y4M20D
CY2024Q3 cadl Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedIntrinsicValue
4247000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
3700000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1184000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
686000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4068000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2152000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10D
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8435000
us-gaap Net Income Loss
NetIncomeLoss
-41104000
us-gaap Net Income Loss
NetIncomeLoss
-26844000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32013569
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32013569
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30369129
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30369129
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1184000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
686000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4068000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2152000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
2800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10D
cadl Noncancelable Operating Lease Expiration Date
NoncancelableOperatingLeaseExpirationDate
2026
us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
0
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10646000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8435000
us-gaap Net Income Loss
NetIncomeLoss
-41104000
us-gaap Net Income Loss
NetIncomeLoss
-26844000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32013569
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32013569
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30369129
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13342695
CY2023Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.45
CY2023Q4 us-gaap Severance Costs1
SeveranceCosts1
700000
CY2024Q1 cadl Final Severance Costs1
FinalSeveranceCosts1
46000
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 cadl Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q3 cadl Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13342695
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14181595
CY2023Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.45
CY2023Q4 us-gaap Severance Costs1
SeveranceCosts1
700000
CY2024Q1 cadl Final Severance Costs1
FinalSeveranceCosts1
46000
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 cadl Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q3 cadl Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false

Files In Submission

Name View Source Status
0000950170-24-126767-index-headers.html Edgar Link pending
0000950170-24-126767-index.html Edgar Link pending
0000950170-24-126767.txt Edgar Link pending
0000950170-24-126767-xbrl.zip Edgar Link pending
cadl-20240930.htm Edgar Link pending
cadl-20240930.xsd Edgar Link pending
cadl-ex31_1.htm Edgar Link pending
cadl-ex31_2.htm Edgar Link pending
cadl-ex32_1.htm Edgar Link pending
cadl-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cadl-20240930_htm.xml Edgar Link completed